Crucial medicine at risk of running out in Hungary

Hungary is on the brink of a healthcare crisis as an essential medicine, insulin, is at risk of running out. In a letter addressed to Hungarian General Practitioners (GPs), the State Secretary for Health, Dr. Péter Takács, warned that disruptions in insulin supply are likely to occur starting in July.

The letter was later shared on social media by pharmacist Dr Szabolcs Dobson. It advises doctors to proactively communicate with nearby pharmacies to determine the availability of specific medications. Furthermore, it proposes that GPs seek suitable alternatives for their patients, writes Pénzcentrum.

Huge shortage

Manufacturing problems and market considerations are believed to be the primary factors contributing to this alarming situation.

Dated 26 June, Dr Takács’ letter explicitly states:

“From 1 July 2023, the availability of certain human insulin products will change. Considering that the recommendations provided by specialists are applicable to all human insulin products, regardless of the specific product mentioned in the recommendation, I urge you to contact your nearest pharmacy to inquire about the availability of human insulin products before prescribing a specific medicine. A new specialist recommendation is not required, and any available insulin product from any manufacturer can be prescribed based on the current recommendation.”

Dr. Takács further emphasises that a new specialist recommendation is unnecessary. Doctors can prescribe any insulin medicine product currently available, regardless of the manufacturer.

Manufacturing problems

The National Institute of Pharmacy and Food Safety (OGYÉI) has identified three human insulin preparations, marketed by Sanofi-Aventis Deutschland GmbH, facing shortages. These insulin products, which come in pre-filled injection pens of 5×3 ml, include Insuman Basal SoloStar 100 IU/ml, Basal SoloStar, Comb 25 SoloStar and Rapid Solostar.

Manufacturing issues have resulted in a shortage of Insuman Basal SoloStar 100 IU/ml. At the same time, market considerations have also contributed to the unavailability of Basal SoloStar, Comb 25 SoloStar and Rapid Solostar in pharmacies.

The potential shortage of insulin poses a severe risk to the well-being of patients who depend on these life-sustaining treatments. Insulin plays a vital role in managing diabetes, and any disruption in its supply can have dire consequences for individuals with the condition.

Source: Pénzcentrum